latest news in Biotechnology
Biotech Firm Cuts Production Costs by Seventy Percent Ahead of Commercial Launch
New York, Thursday, 19 November 2026.
eXoZymes slashed manufacturing costs for its lead compound below $1,000 per kilogram, securing commercial partner Curia despite posting a $2.24 million third-quarter loss and managing $3.26 million in cash.
Zoar Debuts on the New York Stock Exchange Following Landmark Healthcare Merger
New York, Wednesday, 18 November 2026.
Impact Biomedical completed its strategic combination with Zoar Limited, debuting on the public market today backed by Zoar Labs’ $77.7 million annual net income and accelerating pipeline commercialization.
Greener Blood Processing: How a New Filter Eliminates Harmful Chemical Waste
Washington, Wednesday, 18 November 2026.
Sangtech Lab has launched the world’s first commercial inline blood filter produced without organic solvents or wastewater, setting a clean-manufacturing standard that slashes environmental compliance costs for medical supply chains.
Direct Gene Editing Inside the Body Nears First US Health Approval
Washington, Sunday, 15 November 2026.
The FDA’s pending decision on Intellia’s liver-targeted therapy could mark the first medicine to edit genes directly inside patients, bypassing costly laboratory cell modification to expand patient reach.